Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10586712 | 0.88 | SIGMAR1 (0.53) | PARP1PARP2SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL30658590 | 0.88 | SIGMAR1 (0.50) | PARP1PARP2SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL29114059 | 0.88 | SIGMAR1 (0.50) | PARP1PARP2SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL10585573 | 0.87 | SIGMAR1 (0.49) | PARP1PARP2SIGMAR1CYP19A1TBXAS1 | |
| SCHEMBL830267 | 0.84 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL1725811 | 0.83 | BLM (0.50) | PARP1PARP2 | |
| SCHEMBL30572310 | 0.83 | BLM (0.50) | PARP1PARP2 | |
| SCHEMBL15882484 | 0.83 | MTNR1A (0.55) | PARP1PARP2HTR6 | |
| SCHEMBL17335656 | 0.83 | MTNR1A (0.55) | PARP1PARP2HTR6 | |
| SCHEMBL7697230 | 0.83 | HTR2C (0.54) | PARP1PARP2SIGMAR1CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611473-B2 | Double-stranded nucleic acid compounds | QUARK PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150259676-A1 | DOUBLE-STRANDED NUCLEIC ACID COMPOUNDS | QUARK PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2014043291-A1 | DOUBLE-STRANDED NUCLEIC ACID COMPOUNDS | QUARK PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-8389720-B2 | Quinolone neuropeptide S receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | MERCK SHARP & DOHME LLC | 2011-09-01 | — | — | US | disclosed |
| EP-1799637-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | Amgen, Inc (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006036664-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212946-A1 | Quinolone Neuropeptide S Receptor Antagonists | NPSR1, NPY1R, NPY2R | PARP1 2816/4885PARP2 3869/4885SIGMAR1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.